Yan Qin

Yan Qin is a professional with experience as a Principal Scientist at Incendia Therapeutics, Fuhong Therapeutics, and Compass Therapeutics Inc. Prior to these roles, Yan was a Research Fellow at Dana-Farber Cancer Institute and Boston Children's Hospital, focusing on LRRC33/GARP and TGF-beta interaction. Yan also studied HIV and DC interaction at Institut Pasteur as a student. Yan holds a PhD in Biotechnology from the Chinese Academy of Sciences and a Bachelor's degree in Biotechnology from Jilin University.